Novo Nordisk increases commitment to stem cell-based therapies

Novo Nordisk announced an increased commitment to stem cell-based therapies and an expansion of the focus on type 1 diabetes into other serious chronic diseases. This has been made possible through an exclusive collaboration with the University of California San Francisco (UCSF) in which a first milestone in the development of human embryonic stem cell lines has been reached.

Under the terms of the agreement with UCSF, Novo Nordisk has licensed a technology to enable the generation of good manufacturing practice (GMP) compliant human embryonic stem cell (hESC) lines as well as the rights to further develop these into future regenerative medicine therapies.

In early May, the partners reached an important milestone with the inauguration of a new GMP laboratory at UCSF where employees from the university and Novo Nordisk will be working together on deriving the cell lines that are expected to define a new quality standard in production of stem cell-based therapies.


After two decades of intensive research focusing on the differentiation of pluripotent stem cells into insulin-producing beta cells, Novo Nordisk has now achieved preclinical proof-of-concept. Together with Cornell University, Novo Nordisk has also made significant progress in developing an encapsulation device that will protect the beta cells that are transplanted into patients from attack by the immune system. Novo Nordisk anticipates that the first clinical trial could be initiated within the next few years.

“Finding a cure for diabetes is part of Novo Nordisk’s vision and recent progress in our stem cell research and the access to robust and high-quality cell lines raises hopes for people with type 1 diabetes. Our collaboration with UCSF is also expected to accelerate current and future partnerships to develop stem cell-based therapies for the treatment of other serious chronic diseases”, said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.

Stem cell-based therapy is a rapidly growing field that may produce novel treatments for a number of diseases with high unmet medical needs. The development of GMP grade stem cell lines in collaboration with UCSF has enabled Novo Nordisk to expand the focus on serious chronic diseases beyond diabetes.

Through partnerships with the Swedish biotech company Biolamina and Lund University, activities have been initiated to develop stem cell-based treatments for Parkinson’s disease. In another partnership with Biolamina and the DUKE National University Singapore Medical School, the research focus is on chronic heart failure and age-related macular degeneration. Novo Nordisk has the ambition to pursue further collaborations to develop stem cell-based therapies for other serious chronic diseases.


This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

The SARS-CoV-19 outbreak, a global threat
Samsung’s Valentine’s Day campaign ends on a happy note
Grameenphone brings in the iPhone 11 series in Bangladesh
realme officially enters Bangladesh market
The miracle of Hyperbaric Oxygen Therapy (HBOT) and its potential in Bangladesh
WaterAid brings public toilet access cards for Dhaka’s marginalised population


News of the Month

Scroll Up
%d bloggers like this: